HEXIM2

Across TCGA pan-cancer cohorts, HEXIM2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HEXIM2 data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HEXIM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HEXIM2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where HEXIM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.698	1.000	.020	16	view →
LUAD	DFS	Median	III,IV	0.409	0.922	.024	9	view →
PDAC	OS	Median	II,III,IV	0.236	0.578	.021	8	view →
LSCC	OS	Median	III,IV	0.692	0.996	.027	3	view →
GBM	OS	Median	All	0.253	0.524	.032	1	view →
CCRCC	OS	Median	II,III,IV	0.968	0.848	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HEXIM2–HNSC (DFS)

Open the HNSC breakdown →